Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the best stocks you’ll wish you bought sooner.

As of the close of December 2, the consensus shows that analyst opinions are highly favourable towards Corcept Therapeutics Incorporated (NASDAQ:CORT), with 80% of analysts covering it assigning a Buy or equivalent rating, and none assigning a Sell rating. With a consensus 1-year median price target of $137.50, the analysts still see a 70% upside potential.

On November 25, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a bullish stance on the stock, reaffirming his Buy rating and a consensus high price target of $145.00.

The analyst believes that Corcept Therapeutics (NASDAQ:CORT) remains well-positioned for solid growth despite recent commercial challenges with its core product, Korlym. Despite these headwinds, he notes that volume trends have strengthened meaningfully over the past two quarters, supporting the guidance for FY2025 revenue growth of 19%-26%, which implies $800–$850 million in revenue.

Ramakanth also believes that Corcept’s pipeline provides ample medium- to long-term catalyst. The company is advancing its oral therapy relacorilant in two severe disorders, with PDUFA dates of December 30, 2025, for Cushing’s syndrome, and July 11, 2026, for ovarian cancer. The analyst’s estimates suggest that relacorilant could generate up to $4.3 billion in annual revenue by 2034, highlighting significant upside potential.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.